학술논문
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
Document Type
article
Author
Roberta Ramonda; Mariagrazia Lorenzin; Maria Sole Chimenti; Salvatore D’Angelo; Antonio Marchesoni; Carlo Salvarani; Ennio Lubrano; Luisa Costa; Ylenia Dal Bosco; Elena Fracassi; Augusta Ortolan; Mario Ferraioli; Antonio Carriero; Elisa Visalli; Riccardo Bixio; Francesca Desiati; Alberto Bergamini; Elisa Pedrollo; Andrea Doria; Rosario Foti; Antonio Carletto
Source
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Subject
Language
English
ISSN
1759-7218
1759720X
1759720X
Abstract
Objectives: To evaluate, in a multicentric Italian cohort of axial spondyloarthritis (axSpA) patients on Secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and safety of SEC; (2) the drug retention rate and low disease activity (LDA) measured as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)